Cross-Canada survey of resistance of 2747 aerobic blood culture isolates to piperacillin/tazobactam and other antibiotics

Canadian Journal of Infectious Diseases

Volumn 9, Issue 1, 1998, Pages 33-44

  Forward, Kevin R ^a   Franks, Patricia A ^b   Low, Donald E ^b   Rennie, Robert ^b   Simor, Andrew E ^b  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

Antibiotic resistance; Pieperacillin; Susceptibility survey; Tazobactam

Indexed keywords

PIPERACILLIN; TAZOBACTAM;

AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD CULTURE; CANADA; ENTEROBACTERIACEAE; NONHUMAN; PSEUDOMONAS AERUGINOSA;

EID: 0031938517     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/1998/730838     Document Type: Article

References (25)

1. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.
2. Bryson HM, Brogden RN. Piperacillin/tazobactam: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1994;47:506-35.
3. Sanders WE, Sanders CC. Piperacillin-tazobactam: a critical review of the evolving clinical literature. Clin Infect Dis 1996;22:107-23.
4. Shlaes DM, Baughman R, Boylen CT, et al. Piperacillin/ tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection. J Antimicrob Chemother 1994;3:565-77.
5. Sweet RL, Roy S, Faro S, O'Brien WF, Sanfilippo JS, Seidlin M. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. Obstet Gynecol 1993;83:280-5.
6. Tan JS, Wishnow RM, Talan DA, Duncanson FP, Norden CW. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multi-centre study of piperacillin/tazobactam versus ticarcillin/clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group. Antimicrob Agents Chemother 1993;37:1580-6.
7. Moulton Y, Leroy O, Beuscart C. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother 1993;31(Suppl A):87-95.
8. Gorbach SL. Piperacillin/tazobactam in the treatment of polymicrobial infections. Intensive Care Med 1994;20:S27-34.
9. Nowe P. Piperacillin/tazobactam in complicated urinary tract infections. Intensive Care Med 1994;20(Suppl 3):S39-42.
10. Brismar D, Malmborg AS, Tunevall G, et al. Piperacillintazobactam versus imipenem-cilastatin in the treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992;36:2766-74.
11. Niinikoski J, Havia T, Alhava E et al. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infection. Surg Gynecol Obstet 1993;176:255-61.
12. Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995;39-.445-52.
13. Micozzi A, Nucci M, Venditti M, et al. Piperacillin/tazobactam/ amikacin versus piperacillin/amikacin/tiecoplanin in the empirical treatment of neutropenic patients. Eur J Clin Microbiol Infect Dis 1993;12:1-8.
14. Wise R. The efficacy and safety of piperacillin/tazobactam in the therapy of bacteremia. J Antimicrob Chemother 1993;31 (Suppl A):97-104.
15. Charbonneau P. Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy. Intensive Care Med 1994;20-.S43-8.
16. National Committee for Clinical Laboratory Standards (NCCLS) methods for dilution antimicrobial susceptility tests for bacteria that grow aerobically: approved standard M7-A3. Villanova, 1993.
17. National Committee for Clinical Laboratory Standards (NCCLS) Performance standards for antimicrobial susceptibility testing: 5th Informational Supplement, M100-S5. Villanova, 1994.
18. Forward KR, Low DE, Laverdiere M, et al. Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates. Can J Infect Dis 1997;8:147-53.
19. Appelbaum PC, Spangler SK, Jacobs MR. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam. J Antimicrob Chemother 1993;32:223-31.
20. Akova M, Yang Y, Livermore DM. Interactions of tazobactam and clavulanate with inducibly and constitutively expressed Class I beta-lactamases. J Antimicrob Chemother 1990;25:199-208.
21. Knapp CC, Sierra-Madero J, Washington JA. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298, 741) against clinical isolates and against mutants derepressed for class I beta-lactamase. Diagn Microbiol Infect Dis 1989;12:511-5.
22. Fass RJ, Prior RB. Comparative in vitro activities of piperacillintazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother 1989;33:1268-74.
23. Eliopoulos GM, Klimm K, Ferraro MJ, Jacoby GA, Moellering RC Jr. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830). Diagn Microbiol Infect Dis 1989;12:481-8.
24. Garcia-Rodriguez JA, Garcia Sanchez JE, Garcia Garcia MI, Garcia Sanchez E, Munoz Bellido JL. Antibiotic susceptibility profile of Xanthomonas maltophilia in vitro activity of β-lactam/β-lactamase inhibitor combinations. Diagn Microbiol Infect Dis 1991;14:239-43.
25. Sun B, Shapiro T, Jones R, Satishchandran V, Truant AL. In vitro activity of β-lactamase inhibitors against clinical isolates of Acinetobacter species. Diagn Microbiol Infect Dis 1995;21:111-4.